164 related articles for article (PubMed ID: 38592373)
1. Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair.
Ballout F; Lu H; Bhat N; Chen L; Peng D; Chen Z; Chen S; Sun X; Giordano S; Corso S; Zaika A; McDonald O; Livingstone AS; El-Rifai W
Clin Cancer Res; 2024 May; 30(10):2193-2205. PubMed ID: 38592373
[TBL] [Abstract][Full Text] [Related]
2. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
3. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
5. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
6. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
Hassan MS; Williams F; Awasthi N; Schwarz MA; Schwarz RE; Li J; von Holzen U
Sci Rep; 2019 Nov; 9(1):17608. PubMed ID: 31772236
[TBL] [Abstract][Full Text] [Related]
7. ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer.
Bakkenist CJ; Lee JJ; Schmitz JC
Clin Colorectal Cancer; 2018 Dec; 17(4):255-257. PubMed ID: 30316683
[No Abstract] [Full Text] [Related]
8. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma.
Sun X; Martin RCG; Zheng Q; Farmer R; Pandit H; Li X; Jacob K; Suo J; Li Y
Cell Oncol (Dordr); 2018 Dec; 41(6):651-662. PubMed ID: 30116994
[TBL] [Abstract][Full Text] [Related]
9. Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma.
Feingold PL; Surman DR; Brown K; Xu Y; McDuffie LA; Shukla V; Reardon ES; Crooks DR; Trepel JB; Lee S; Lee MJ; Gao S; Xi S; McLoughlin KC; Diggs LP; Beer DG; Nancarrow DJ; Neckers LM; Davis JL; Hoang CD; Hernandez JM; Schrump DS; Ripley RT
Mol Cancer Ther; 2018 Sep; 17(9):2013-2023. PubMed ID: 29934340
[TBL] [Abstract][Full Text] [Related]
10. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S; Morishita A; Ogawa K; Tadokoro T; Chiyo T; Kato K; Kobara H; Mori H; Iwama H; Masaki T
Oncotarget; 2017 Jan; 8(5):8536-8549. PubMed ID: 28052030
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Cancer Res Treat; 2020 Jan; 52(1):149-166. PubMed ID: 31291716
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer.
Hu W; Lei L; Xie X; Huang L; Cui Q; Dang T; Liu GL; Li Y; Sun X; Zhou Z
Cell Death Dis; 2019 Jul; 10(8):550. PubMed ID: 31320608
[TBL] [Abstract][Full Text] [Related]
13. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
14. Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.
MacGregor TP; Carter R; Gillies RS; Findlay JM; Kartsonaki C; Castro-Giner F; Sahgal N; Wang LM; Chetty R; Maynard ND; Cazier JB; Buffa F; McHugh PJ; Tomlinson I; Middleton MR; Sharma RA
Sci Rep; 2018 May; 8(1):7265. PubMed ID: 29739952
[TBL] [Abstract][Full Text] [Related]
15. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
Fu QH; Zhang Q; Zhang JY; Sun X; Lou Y; Li GG; Chen ZL; Bai XL; Liang TB
Tumour Biol; 2016 Jun; 37(6):7277-86. PubMed ID: 26666823
[TBL] [Abstract][Full Text] [Related]
16. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage.
Zhou Z; Lu H; Zhu S; Gomaa A; Chen Z; Yan J; Washington K; El-Rifai W; Dang C; Peng D
J Exp Clin Cancer Res; 2019 Jan; 38(1):13. PubMed ID: 30626422
[TBL] [Abstract][Full Text] [Related]
17. ATM/ATR and SMAD3 pathways contribute to 3-indole-induced G₁ arrest in cancer cells and xenograft models.
Huang SM; Lu KT; Wang YC
Anticancer Res; 2011 Jan; 31(1):203-8. PubMed ID: 21273599
[TBL] [Abstract][Full Text] [Related]
18. IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.
Myers AL; Lin L; Nancarrow DJ; Wang Z; Ferrer-Torres D; Thomas DG; Orringer MB; Lin J; Reddy RM; Beer DG; Chang AC
Oncotarget; 2015 Sep; 6(28):25897-916. PubMed ID: 26317790
[TBL] [Abstract][Full Text] [Related]
19. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.
Hong J; Katsha A; Lu P; Shyr Y; Belkhiri A; El-Rifai W
Cancer Res; 2012 Sep; 72(17):4504-14. PubMed ID: 22745369
[TBL] [Abstract][Full Text] [Related]
20. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
